BACKGROUND AND PURPOSE - The aim of the present study was to characterize the role of PAR1 in rat bladder under inflammatory conditions, and determine whether a selective PAR1 antagonist, namely F16357, can prevent the pathophysiological parameters of CYP-induced IC.
EXPERIMENTAL APPROACH - Immunohistochemistry, contractile activity in isolated bladder and urodynamics were performed before and after CYP treatment. F16357 was administered intravesically during the acute phase of inflammation and effects on PAR1 receptors and PAR1-related bladder contraction were evaluated 24H after CYP injection. For telemetric experiments, urodynamics and associated voided volumes were recorded 7H and 24H after CYP. This article is protected by copyright. All rights reserved.
British journal of pharmacology. 2016 Apr 25 [Epub ahead of print]
Nicolas Monjotin, James Gillespie, Martine Farrie, Bruno Le Grand, Didier Junquero, Nathalie Vergnolle
Institut de Recherche Pierre Fabre, Castres, France., Newcastle University, Newcastle upon Tyne, England., Institut de Recherche Pierre Fabre, Castres, France., Institut de Recherche Pierre Fabre, Castres, France., Institut de Recherche Pierre Fabre, Castres, France., IRSD, Université de Toulouse, INSERM, INRA, INP-ENVT, Université de Toulouse-3 Paul Sabatier, Toulouse, France.